{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:03Z","timestamp":1786982763989,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s40266-017-0461-y","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T01:20:25Z","timestamp":1492564825000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Lesinurad: A Review in Hyperuricaemia of Gout"],"prefix":"10.1007","volume":"34","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"issue":"10055","key":"461_CR1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039\u201352.","journal-title":"Lancet."},{"issue":"1","key":"461_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12325-014-0175-z","volume":"32","author":"F Perez-Ruiz","year":"2015","unstructured":"Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015;32(1):31\u201341.","journal-title":"Adv Ther."},{"issue":"1","key":"461_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis."},{"key":"461_CR4","unstructured":"National Kidney Foundation. Gout, hyperuricemia & chronic kidney disease. 2016. https:\/\/www.kidney.org\/atoz\/content\/gout . Accessed 24 Mar 2017."},{"key":"461_CR5","doi-asserted-by":"crossref","unstructured":"Khanna P, Tafesse E, Baumgartner S, et al. Comparing the burden of illness of patients with tophaceous and non-tophaceous gout in France, Germany, Italy, Spain, UK, and USA [abstract no. 226]. Arthritis Rheumatol. 2016;68(Suppl 10).","DOI":"10.1136\/annrheumdis-2016-eular.3870"},{"issue":"7","key":"461_CR6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s12325-016-0346-1","volume":"33","author":"F Nyberg","year":"2016","unstructured":"Nyberg F, Horne L, Morlock R, et al. Comorbidity burden in trial-aligned patients with established gout in Germany, UK, US, and France: a retrospective analysis. Adv Ther. 2016;33(7):1180\u201398.","journal-title":"Adv Ther."},{"issue":"10","key":"461_CR7","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res."},{"key":"461_CR8","unstructured":"Zurampic\u00ae (lesinurad) tablets, for oral use: US prescribing information. 2016. http:\/\/irwdpi.com\/zurampic\/zurampic.pdf . Accessed 3 Apr 2017."},{"key":"461_CR9","unstructured":"Gr\u00fcnenthal GmbH. Zurampic 200 mg film-coated tablets: EU summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/ . Accessed 24 Mar 2017."},{"issue":"1","key":"461_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","volume":"18","author":"J Miner","year":"2016","unstructured":"Miner J, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18(1):214.","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"461_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40261-016-0386-y","volume":"36","author":"Z Shen","year":"2016","unstructured":"Shen Z, Yeh LT, Wallach K, et al. In vitro and in vivo interaction studies between lesinurad, a selective urate reabsorption inhibitor, and major liver or kidney transporters. Clin Drug Investig. 2016;36(6):443\u201352.","journal-title":"Clin Drug Investig."},{"key":"461_CR12","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.2147\/DDDT.S85193","volume":"9","author":"Z Shen","year":"2015","unstructured":"Shen Z, Rowlings C, Kerr B, et al. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Des Devel Ther. 2015;9:3423\u201334.","journal-title":"Drug Des Devel Ther."},{"issue":"6","key":"461_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","volume":"75","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75(6):1074\u201380.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"461_CR14","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","volume":"53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Kerr B, Yeh LT, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology. 2014;53(12):2167\u201374.","journal-title":"Rheumatology."},{"issue":"1","key":"461_CR15","first-page":"203","volume":"69","author":"KG Saag","year":"2017","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol. A randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis. Rheumatol. 2017;69(1):203\u201312.","journal-title":"Rheumatol."},{"key":"461_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209213","author":"T Bardin","year":"2016","unstructured":"Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2016. doi: 10.1136\/annrheumdis-2016-209213 .","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 2","key":"461_CR17","first-page":"778","volume":"74","author":"N Dalbeth","year":"2015","unstructured":"Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a novel selective uric acid reabsorption inhibitor, in combination with febuxostat, in patients with tophaceous gout: the CRYSTAL phase III clinical trial [abstract no. SAT0329 plus poster]. Ann Rheum Dis. 2015;74(Suppl 2):778.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 2","key":"461_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1136\/annrheumdis-2016-eular.6201","volume":"75","author":"KG Saag","year":"2016","unstructured":"Saag KG, Becker MA, Storgard C, et al. Examination of serum uric acid (SUA) lowering and safety with extended treatment with lesinurad and allopurinol in subjects with gout [abstract no. THU0495]. Ann Rheum Dis. 2016;75(Suppl 2):371.","journal-title":"Ann Rheum Dis."},{"key":"461_CR19","doi-asserted-by":"crossref","unstructured":"Bardin T, Dalbeth N, Terkeltaub R, et al. Clinical response of tophus and flares to extended use of lesinurad in combination with a xanthine oxidase inhibitor in patients with gout [abstract no. 209]. Arthritis Rheumatol. 2016;68(Suppl 10).","DOI":"10.1136\/annrheumdis-2016-eular.3140"},{"key":"461_CR20","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.2147\/DDDT.S114455","volume":"10","author":"Z Shen","year":"2016","unstructured":"Shen Z, Gillen M, Tieu K, et al. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT\/QTc study. Drug Des Devel Ther. 2016;10:3509\u201317.","journal-title":"Drug Des Devel Ther."},{"key":"461_CR21","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.2147\/DDDT.S119944","volume":"10","author":"M Gillen","year":"2016","unstructured":"Gillen M, Valdez S, Zhou D, et al. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers. Drug Des Devel Ther. 2016;10:3555\u201362.","journal-title":"Drug Des Devel Ther."},{"key":"461_CR22","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT01510769. 2016. https:\/\/clinicaltrials.gov . Accessed 24 Mar 2017."},{"key":"461_CR23","unstructured":"Dalbeth N, Jones G, Terkeltaub R, et al. Efficacy and safety in patients with tophaceous gout receiving lesinurad and febuxostat combination therapy: interim analysis of an extension study [abstract no. 2352]. Arthritis Rheumatol. 2015;67(Suppl 10)."},{"key":"461_CR24","unstructured":"Saag KG, Bardin T, So A, et al. Analysis of gout subjects receiving lesinurad and allopurinol combination therapy by baseline renal function [abstract no. 2112]. Arthritis Rheumatol. 2015;67(Suppl 10)."},{"key":"461_CR25","unstructured":"Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad and febuxostat combination therapy: analysis of treatment based on patient baseline renal function [abstract no. 2353]. Arthritis Rheumatol. 2015;67(Suppl 10)."},{"issue":"Suppl 2","key":"461_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/annrheumdis-2016-eular.6412","volume":"75","author":"PP Khanna","year":"2016","unstructured":"Khanna PP, Baumgartner S, Robinson J. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with xanthane oxidase inhibitors: SUA and flares composite endpoint from phase III studies in gout patients (CLEAR 1, CLEAR 2 and CRYSTAL) [abstract no. THU0527]. Ann Rheum Dis. 2016;75(Suppl 2):382\u20133.","journal-title":"Ann Rheum Dis."},{"key":"461_CR27","doi-asserted-by":"crossref","unstructured":"Becker MA, Keenan RT, Khanna P, et al. Integrated safety of lesinurad, a novel uric acid reabsorption inhibitor for the treatment of gout [abstract no. 207]. Arthritis Rheumatol. 2016;68(Suppl 10).","DOI":"10.1136\/annrheumdis-2017-eular.3674"},{"key":"461_CR28","doi-asserted-by":"crossref","unstructured":"Terkeltaub R, Malamet R, Bos K, et al. Renal safety of lesinurad: a pooled analysis of phase III and extension studies [abstract no. 206]. Arthritis Rheumatol. 2016;68(Suppl 10).","DOI":"10.1136\/annrheumdis-2017-eular.4632"},{"issue":"4","key":"461_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1759720X16646703","volume":"8","author":"SE Sattui","year":"2016","unstructured":"Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016;8(4):145\u201359.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"6","key":"461_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11926-016-0579-7","volume":"18","author":"RT Keenan","year":"2016","unstructured":"Keenan RT, Schlesinger N. New and pipeline drugs for gout. Curr Rheumatol Rep. 2016;18(6):32.","journal-title":"Curr Rheumatol Rep."},{"key":"461_CR31","doi-asserted-by":"publisher","unstructured":"Terkeltaub R. Emerging uricosurics for gout. Expert Rev Clin Pharmacol. 2016:1\u20133. doi: 10.1080\/17512433.2017.1271709 .","DOI":"10.1080\/17512433.2017.1271709"},{"issue":"4","key":"461_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1517\/17425255.2012.667401","volume":"8","author":"EI Lepist","year":"2012","unstructured":"Lepist EI, Ray AS. Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol. 2012;8(4):433\u201348.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"1","key":"461_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12012-011-9145-8","volume":"12","author":"N Robbins","year":"2012","unstructured":"Robbins N, Koch SE, Tranter M, et al. The history and future of probenecid. Cardiovasc Toxicol. 2012;12(1):1\u20139.","journal-title":"Cardiovasc Toxicol."},{"issue":"Suppl 2","key":"461_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/annrheumdis-2015-eular.1188","volume":"74","author":"R Terkeltaub","year":"2015","unstructured":"Terkeltaub R, Perez-Ruiz F, Storgard C, et al. Relationship between sustained lowering of serum urate levels and improvements in gout flares and tophus area: pooled exploratory analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitor combination therapy [abstract no. SAT0313]. Ann Rheum Dis. 2015;74(Suppl 2):771\u20132.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"461_CR35","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3899\/jrheum.151199","volume":"43","author":"R Wood","year":"2016","unstructured":"Wood R, Fermer S, Ramachandran S, et al. Patients with gout treated with conventional urate-lowering therapy: association with disease control, health-related quality of life, and work productivity. J Rheumatol. 2016;43(10):1897\u2013903.","journal-title":"J Rheumatol."},{"issue":"Suppl 2","key":"461_CR36","first-page":"655","volume":"75","author":"P Khanna","year":"2016","unstructured":"Khanna P, Baumgartner S, Robinson J. The impact of gout flares on patient-reported assessments of pain and disability [abstract no. FRI0589 plus poster]. Ann Rheum Dis. 2016;75(Suppl 2):655\u20136.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"461_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/M16-0570","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58\u201368.","journal-title":"Ann Intern Med."},{"key":"461_CR38","unstructured":"Singh JA, Storgard C, Baumgartner S, et al. Use of high-dose allopurinol to reach serum uric acid targets in patients with gout across multiple countries [abstract no. 1186]. In: ACR\/ARHP Annual Meeting; 2013."},{"issue":"2","key":"461_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","volume":"45","author":"MA Becker","year":"2015","unstructured":"Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015;45(2):174\u201383.","journal-title":"Semin Arthritis Rheum."},{"issue":"11","key":"461_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40266-014-0214-0","volume":"31","author":"LK Stamp","year":"2014","unstructured":"Stamp LK, Chapman PT. Urate-lowering therapy: current options and future prospects for elderly patients with gout. Drugs Aging. 2014;31(11):777\u201386.","journal-title":"Drugs Aging."},{"issue":"2","key":"461_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/BOR.0000000000000035","volume":"26","author":"MH Bach","year":"2014","unstructured":"Bach MH, Simkin PA. Uricosuric drugs: the once and future therapy for hyperuricemia? Curr Opin Rheumatol. 2014;26(2):169\u201375.","journal-title":"Curr Opin Rheumatol."},{"key":"461_CR42","unstructured":"Stack A, Blak B, Johnson M, et al. Association of gout with risk of advanced chronic kidney disease [abstract no. 3188]. Arthritis Rheumatol. 2016;68(Suppl 10)."},{"key":"461_CR43","doi-asserted-by":"publisher","unstructured":"Borghi C, Nuevo J, Medina J, et al. Association between serum uric acid levels and cardiovascular risk. A post hoc analysis of the European Cardiovascular Risk Patients: Disease Prevention and Management in Usual Daily Practice (EURIKA) Study [poster no. FRI0337]. In: 16th EULAR Annual European Congress of Rheumatology; 2015.","DOI":"10.1136\/annrheumdis-2015-eular.5057"},{"key":"461_CR44","doi-asserted-by":"publisher","unstructured":"Baumgartner S, Morlock R. Hyperuricemia and the risk for cardiovascular disease: individual patient meta-analysis of 77,045 individuals enrolled in 15 epidemiologic studies [poster no. FRI0591]. In: EULAR Annual European Congress of Rheumatology; 2016.","DOI":"10.1136\/annrheumdis-2016-eular.3931"},{"key":"461_CR45","doi-asserted-by":"crossref","unstructured":"Cheetham TC, Nichols GA, Harrold LR, et al. The association between serum uric acid levels and acute myocardial infarction in incident gout patients [abstract no. PMS18]. In: ISPOR 21st Annual International Meeting; 2016.","DOI":"10.1016\/j.jval.2016.03.1175"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-017-0461-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:02:05Z","timestamp":1750186925000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-017-0461-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["461"],"URL":"https:\/\/doi.org\/10.1007\/s40266-017-0461-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]}}}